Zenas BioPharma, Inc. beat EPS estimates 20% of the time across 5 reported quarters (1 beats, 4 misses), averaging -27.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.89 | $-1.77 | -98.9% | Miss | |
| Q1 FY26 | $-1.37 | $-1.46 | -6.6% | Miss | |
| Q4 FY25 | not reported | $-1.40 | not reported | not reported | |
| Q3 FY25 | $-0.87 | $-1.22 | -40.2% | Miss | |
| Q2 FY25 | $-1.02 | $-1.25 | -22.6% | Miss | |
| Q1 FY25 | $-1.15 | $-0.80 | +30.4% | Beat | |
| Q3 FY24 | not reported | $-5.02 | not reported | not reported |
Back to ZBIO overview · ZBIO holders · ZBIO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.